{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:25:39Z","timestamp":1791588339771,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81770875, 81572639"],"award-info":[{"award-number":["No.81770875, 81572639"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00520-020-05355-7","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T19:03:47Z","timestamp":1581707027000},"page":"2533-2540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency"],"prefix":"10.1007","volume":"28","author":[{"given":"Mei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-7664","authenticated-orcid":false,"given":"Xijie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"issue":"4","key":"5355_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1309\/AJCPYO5FSV3UPEXS","volume":"143","author":"A Soni","year":"2015","unstructured":"Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, Wei S (2015) Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol 143(4):471\u2013478. https:\/\/doi.org\/10.1309\/AJCPYO5FSV3UPEXS","journal-title":"Am J Clin Pathol"},{"key":"5355_CR2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.breast.2016.09.017","volume":"30","author":"O Awolaran","year":"2016","unstructured":"Awolaran O, Brooks SA, Lavender V (2016) Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence. Breast 30:156\u2013171. https:\/\/doi.org\/10.1016\/j.breast.2016.09.017","journal-title":"Breast"},{"key":"5355_CR3","unstructured":"Wong MH, Stockler MR, Pavlakis N Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev (2):CD003474"},{"issue":"35","key":"5355_CR4","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/jco.2017.75.4614","volume":"35","author":"C Van Poznak","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol 35(35):3978\u20133986. https:\/\/doi.org\/10.1200\/jco.2017.75.4614","journal-title":"J Clin Oncol"},{"issue":"3","key":"5355_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jbo.2013.05.001","volume":"2","author":"B Hutton","year":"2013","unstructured":"Hutton B, Addison CL, Campbell K, Fergusson D, Mazarello S, Clemons M (2013) A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. J Bone Oncol 2(3):123\u2013131","journal-title":"J Bone Oncol"},{"issue":"11","key":"5355_CR6","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1093\/annonc\/mdv284","volume":"26","author":"MFK Ibrahim","year":"2015","unstructured":"Ibrahim MFK, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, Hutton B, Clemons M (2015) Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol 26(11):2205\u20132213","journal-title":"Ann Oncol"},{"key":"5355_CR7","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.2147\/CMAR.S176811","volume":"10","author":"C Liu","year":"2018","unstructured":"Liu C, Wang L, Liu L, Zhuang J, Tang S, Zhou C, Feng F, Liu R, Zhang J, Zhang T, Gao C, Li H, Li J, Sun C (2018) Efficacy and safety of de-escalation bone-modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis. Cancer Manag Res 10:3809\u20133823","journal-title":"Cancer Manag Res"},{"key":"5355_CR8","doi-asserted-by":"crossref","unstructured":"Awan AA, Hutton B, Hilton J, Mazzarello S, Van Poznak C, Vandermeer L, Bota B, Stober C, Sienkiewicz M, Fergusson D, Shorr R, Clemons M (2019) De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat","DOI":"10.1007\/s10549-019-05265-1"},{"issue":"52","key":"5355_CR9","doi-asserted-by":"publisher","first-page":"90308","DOI":"10.18632\/oncotarget.19856","volume":"8","author":"L Cao","year":"2017","unstructured":"Cao L, Yang YJ, Diao JD, Zhang XH, Liu YL, Wang BY, Li ZW, Liu SX (2017) Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis. Oncotarget 8(52):90308\u201390314. https:\/\/doi.org\/10.18632\/oncotarget.19856","journal-title":"Oncotarget"},{"issue":"3","key":"5355_CR10","first-page":"e123","volume":"3","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 3(3):e123\u2013e130","journal-title":"Open Med"},{"issue":"11","key":"5355_CR11","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"issue":"2","key":"5355_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1177\/016327870102400203","volume":"24","author":"F Song","year":"2001","unstructured":"Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR (2001) Methods for exploring heterogeneity in meta-analysis. Eval Health Prof 24(2):126\u2013151. https:\/\/doi.org\/10.1177\/016327870102400203","journal-title":"Eval Health Prof"},{"issue":"7","key":"5355_CR13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14(7):663\u2013670","journal-title":"Lancet Oncol"},{"issue":"5","key":"5355_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/COC.0b013e3182568f7a","volume":"36","author":"E Amir","year":"2013","unstructured":"Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A, Tannock IF, Clemons M (2013) Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol 36(5):436\u2013442","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"5355_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O\u2019Connor T, Velasco MR, Weckstein D, O\u2019Mara A, Loprinzi CL, Shapiro CL (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317(1):48\u201358","journal-title":"JAMA"},{"issue":"7","key":"5355_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"GN Hortobagyi","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncology 3(7):906\u2013912","journal-title":"JAMA Oncology"},{"issue":"1","key":"5355_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"issue":"1","key":"5355_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1):36\u201343. https:\/\/doi.org\/10.1002\/cncr.11892","journal-title":"Cancer"},{"issue":"16","key":"5355_CR19","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48(16):3082\u20133092. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002","journal-title":"Eur J Cancer"},{"issue":"35","key":"5355_CR20","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","volume":"35","author":"CL Shapiro","year":"2017","unstructured":"Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ (2017) Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin Oncol 35(35):3949\u20133955","journal-title":"J Clin Oncol"},{"issue":"1","key":"5355_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/bjc.1987.13","volume":"55","author":"RE Coleman","year":"1987","unstructured":"Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55(1):61\u201366. https:\/\/doi.org\/10.1038\/bjc.1987.13","journal-title":"Br J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-020-05355-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05355-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T21:21:00Z","timestamp":1613251260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-020-05355-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["5355"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05355-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}